Global Dilated Cardiomyopathy Therapeutics Market - 2022-2029

Market Overview

Dilated Cardiomyopathy Therapeutics Market size was valued at US$ 404.9 million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5.90% during the forecast period (2022-2029).

Dilated cardiomyopathy (DCM) is an abnormality of the heart muscle, usually starting in your heart's main pumping chamber (left ventricle). The ventricle becomes weakened and enlarged and can't pump blood. A common cause of heart failure is the heart's inability to supply the body with enough blood, and dilated cardiomyopathy also contributes to irregular heartbeats (arrhythmias), blood clots, or sudden death. People of all ages are affected by DCM, including infants and children, but it is most common in men ages 20 to 50.

Market Dynamics

The global dilated cardiomyopathy therapeutics market growth driven by certain factors such by rising prevalence of heart problems, the increasing number of people suffering from cardiac muscle infections, and drug or alcohol abuse.

Rising prevalence of heart problems, is expected to drive the global dilated cardiomyopathy therapeutics market during the forecast period

Dilated cardiomyopathy accounts for 30-40% of the total number of congestive heart failures each year. The estimated prevalence of dilated cardiomyopathy is 1:2500. This condition is one of the most common causes of heart failure. The incidence of dilated cardiomyopathy discovered at autopsy is estimated to be 4.5 cases per 100,000 population per year, whereas the clinical incidence is 2.45 cases per 100,000 population per year. The increasing incidence of congestive heart diseases has created an urgent need for effective drugs and treatment, thereby benefitting the dilated cardiomyopathy therapeutics market.

According to statistics from the World Health Organization (WHO) for 2020, ischemic heart disease is to blame for 16% of all fatalities worldwide. According to a February 2020 article titled "Heart failure (HF) in France: Chronic Heart Failure Therapeutic Management and Risk of Cardiac Decompensation in Real-Life Setting," approximately one million people in France would be affected by HF. Despite well-defined treatment management, there are nearly 70,000 HF-related deaths and more than 150,000 hospitalizations.

With the rising demand for dilated cardiomyopathy treatment, several major companies have initiated to carry out clinical trials to develop drugs for dilated cardiomyopathy. There is no specific FDA-approved drug for dilated cardiomyopathy because of which the treatment administered is the same as that for congestive heart failure.

Some of the emerging drugs for the treatment of dilated cardiomyopathy are:

ARRY-371797, also known as ARRY-797, is an oral, p38 mitogen-activated protein kinase (MAPK) inhibitor discovered by Array scientists. It is under phase III trial to treat patients suffering from dilated cardiomyopathy because of a Lamin A/C gene mutation. In 2019, Pfizer acquired Array Biopharma to expand its pipeline. This drug is in phase III pipeline drugs of Pfizer under the name PF-07265803 for the treatment of patients affected by dilated cardiomyopathy.

In February 2020, a Keio University research team was given the green light to transplant heart muscle cells derived from iPS cells into patients who have experienced severe heart failure. The study aims to conduct study by the end of 2020 and targets patients with dilated cardiomyopathy, which lowers the systolic function of heart muscle cells.

Side effects associated with dilated cardiomyopathy therapeutics hampering the growth of the market

However, the side effects of dilated cardiomyopathy therapeutics that cause serious discomfort to the patients are restraining the market. Moreover, the availability of implantable devices and promising gene therapy are acting as roadblocks to the market.

Industry Analysis

The global dilated cardiomyopathy therapeutics market provides in-depth analysis of the market based on various industry factors such as porter's five force analysis, pipeline analysis, regulatory analysis, regulatory analysis, epidemiology, unmet needs etc.

Segment Analysis

The drug class segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Based on drug class, the dilated cardiomyopathy therapeutics market is segmented by drug class into angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, aldosterone antagonists, angiotensin II receptor blockers, and others. The angiotensin II receptor blockers drug class is estimated to account for the largest market share, owing to the rising demand for blockbuster drugs in dilated cardiomyopathy treatment, especially in developed regions.

On the other hand, the aldosterone antagonists are expected to grow at the highest CAGR over the forecast period due to the identified positive impact of aldosterone antagonists when used in combination with either ARBs or ACE inhibitors in reducing the progression of Duchenne muscular dystrophy (DMD). Approval for this indication would further accelerate the overall sales of aldosterone antagonists, which would positively impact market growth. According to some studies, the angiotensin receptor blockers such as valsartan can reduce the probability of hospitalization by 28%. These drugs are also effective for patients with systolic heart disease by reducing deaths by 37% and reducing hospitalization frequency. Common anti-arrhythmia medications include amiodarone, procainamide, and lidocaine. Corlanor is a hyperpolarization-activated cyclic nucleotide-gated channel blocker that reduces the cardiac sinus node's spontaneous pacemaker activity. The US FDA approval of Corlanor (ivabradine) for the treatment of stable symptomatic heart failure (HF) due to dilated cardiomyopathy in pediatric patients aged 6 months to 18 years was based on a randomized, double-blind, placebo-controlled trial in 116 patients aged 6 months to less than 18 years with symptomatic DCM in sinus rhythm, NYHA/Ross class II to IV HF, and left ventricular ejection fraction ≤45%. The study's primary endpoint was ≥ a 20% reduction in resting heart rate from baseline without bradycardia or symptoms after an initial titration period.

Geographical Analysis

North America region holds the largest market share of the global dilated cardiomyopathy therapeutics market

The rising incidence of cardiovascular diseases, well-established insurance policies, and the availability of advanced healthcare infrastructure are the major factors. In the USA, the total cost of care (direct and indirect costs) for HF in 2020 is estimated at $43.6 billion, with over 70% of costs attributed to medical costs. In this region, the United States holds the largest market share due to rising geriatric populations, an increasing number of heart diseases in the country, which boosts the demand in this region. Hence, as the number of cardiovascular diseases increases, the market for dilated cardiomyopathy also increases.

Besides, the market players are investing in research and development to conduct new treatment drugs for dilated cardiomyopathy. For instance, in July 2019, Recursion Pharmaceuticals, which uses artificial intelligence to discover drugs, has raised $121 million in a round led by Baillie Gifford. The company is a new drug discovery start-up to raise funds in 2018, as investors flock to the sector hoping that the costly and cumbersome process of finding a drug will be transformed by techniques such as computer vision and machine learning. Recursion is trying to make its own drugs for rare diseases and partner with major pharmaceutical companies such as Takeda and Sanofi on other rare diseases, and hoping to sign deals with pharma companies in areas such as oncology and inflammation.

Competitive Landscape

The global dilated cardiomyopathy therapeutics market is moderately competitive with several major players, including Zensun Shanghai Sci & Tech Co Ltd, Capricor Therapeutics, Inc, AstraZeneca plc., Vericel Corporation, Pfizer Inc., t2cure GmbH, MyoKardia, Kasiak Research Pvt. Ltd., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the growth of the dilated cardiomyopathy therapeutics market globally. For instance, in October 2019, Novartis received the U.S. Food and Drug Administration (FDA) approval for Entresto (sacubitril/valsartan) for the treatment of symptomatic heart failure (HF) with systemic left ventricular systolic dysfunction in pediatric patients aged 1 year and older. Entresto reduces NT-proBNP and is expected to improve cardiovascular outcomes.

Key Companies to Watch

Pfizer Inc

Overview: Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer Limited has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

Product Portfolio: Camzyos is the first novel therapy option available for cardiomyopathy patients.

Key Developments: In August, 18th 2022, Pfizer discontinued the development of dilated cardiomyopathy drug emprumapimod.

The global dilated cardiomyopathy therapeutics market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.